Antibiotic utilization, sensitivity, and cost in the medical intensive care unit of a tertiary care teaching hospital in Nepal

Nirmal Raj Marasine¹,², Shakti Shrestha³, Sabina Sankhi⁴, Nabina Paudel⁵, Ashish Gautam² and Arjun Poudel⁶

Abstract
Background: High utilization and irrational use of antibiotics in an intensive care unit increases microbial resistance, morbidity, mortality, and costs.
Objective: This study aimed to evaluate the utilization, sensitivity and cost analysis of antibiotics used in the medical intensive care unit of a tertiary care teaching hospital of Nepal.
Methods: A prospective cohort study was conducted on patients admitted to the medical intensive care unit at a tertiary care teaching hospital in central Nepal from July to September 2016. Antibiotic utilization, defined daily dose per 100 bed-days and the cost of antibiotics per patient were calculated. Descriptive statistics were performed using IBM-SPSS 20.0.
Results: A total of 365 antibiotics were prescribed in 157 patients during the study period, with an average of 2.34 prescriptions per patient. Total antibiotic utilization in terms of defined daily dose per 100 bed-days was 49.5. Piperacillin/tazobactam (45.2%) was the most commonly prescribed antibiotic, and meropenem was the most expensive antibiotics (US$4440.70). The median (interquartile range) cost of antibiotics used per patient was US$47.67 (US$63.73). Escherichia coli, Acinetobacter, and Pseudomonas sp. were the common organisms isolated and were found to be resistant to some of the commonly used antibiotics.
Conclusion: This study suggests that the utilization and cost of antibiotics are high in medical intensive care unit of the hospital and E. coli was resistant to multiple antibiotics. The findings highlight an urgent need for the implementation of antibiotic stewardship program in order to improve antibiotic utilization in such hospital settings.

Keywords
Antibiotics, cost analysis, drug utilization study, defined daily dose, medical intensive care unit

Date received: 11 May 2021; accepted: 15 August 2021

Introduction
Antibiotics are the most frequently prescribed medicine in the intensive care unit (ICU).¹ ICUs provide specialized healthcare services to critically ill patients, but evidence suggests a high prevalence of infections in patients admitted to these facilities.² High level of staffing, frequent and extended use of broad-spectrum antibiotics, and exposure of patients to invasive procedures usually make it a susceptible place for infection to the admitted patients.³ Up to 30% patients in the ICU can acquire a nosocomial infection which tends to be 5–10 times superior to non-ICU patients.⁴ Consequently, the antibiotic consumption in the ICU is approximately 10 times higher than the general ward of the hospital, accounting for a significant portion of the total hospital antibiotic consumption and related costs.⁵

In several countries, antibiotic resistance in the ICU setting is emerging as a significant and challenging health problem influencing patient outcomes.⁶–⁸ Treatment of bacterial infections such as sepsis, intra-abdominal infections, and meningitis

¹Department of Pharmacy, Karnali College of Health Science, Kathmandu, Nepal
²School of Pharmacy, Chitwan Medical College, Bharatpur, Nepal
³School of Pharmacy, University of Queensland, Brisbane, QLD, Australia
⁴Department of Pharmacy, Modern Technical College, Lalitpur, Nepal
⁵School of Pharmacy, Kathmandu University, Dhulikhel, Nepal
⁶School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD, Australia

Corresponding author:
Nirmal Raj Marasine, Department of Pharmacy, Karnali College of Health Science, Gaushala, Kathmandu, 44600, Nepal.
Email: nirmalmarasine@gmail.com
is becoming difficult as bacteria develop resistance to the antibiotics making the treatment less effective. Antibiotic resistance leads to longer hospitalization, increased healthcare cost, decreased therapeutic outcome, and eventually increased mortality. For instance, the estimated annual cost of antibiotic resistance in Europe was €9 billion. Similarly, death of 25,000 people was reported as a direct consequence of multidrug resistance bacterial infection from the same continent.

Merely the use of antibiotics does not result in resistance, but it is the misuse, increased use, or irrational use associated with antibiotics that create resistance. Self-medication, antibiotics dispensed by non-qualified personnel, patients not completing the full course of prescribed antibiotics, and inconsistent adherence to the treatment regimen are the major forms of irrational drug use that contributes to the development of resistance toward antibiotics. Increased antibiotic consumption increases the emergence and spread of resistant organisms. Prescribing antibiotics to treat common conditions such as upper respiratory tract infections and asymptomatic bacteriuria, inadequate knowledge on proper indication and prescribing guidelines, inadequate counseling, and high charge for a physician visit are the common reasons that lead to antibiotic overuse. Likewise, perception of people that antibiotics heal faster than any other medicines and pressure to prescribe antibiotics, and the lack of education about antibiotic resistance in community level adds to its overuse. Rise in the number of resistant organisms leads to an increased consumption of antibiotics as they become insensitive to the usual dose, and thus require a higher dose to treat the same conditions.

Understanding the utilization pattern of antibiotics and their sensitivity toward the microbes can provide an estimate of the burden and effectiveness of antibiotics. However, there is a paucity of data on antibiotic prescription, consumption patterns and cost from ICU setting in Nepal. Therefore, we aimed to explore the antibiotic utilization, sensitivity and cost analysis in patients admitted in ICU of a tertiary care hospital of Central Nepal.

Methods

Study design, site, population, and sample size

A prospective study was conducted in a 17-bed medical intensive care unit (MICU) of Chitwan Medical College Teaching Hospital (CMCTH), Bharatpur, Nepal. CMCTH is a 750-bed tertiary care hospital of central Nepal. The study was conducted between July and September 2016 among patients aged ≥18 years, admitted to the MICU and prescribed at least one antibiotic. Patients admitted in department other than MICU were excluded from the study. A total of 157 patients were included during the study period.

Data collection

Data were collected prospectively from the patients’ Kardex. Kardex is the prescription and administration record of a patient. Usually in Nepal, Kardex are manually entered and therefore, to verify the record, we communicated with physician and nurses. All the patients were followed up till their stay in the MICU, which included being shifted to other ward or referred to other centers for further management or discharged by the hospital or discharged on request (DOR) by a patient party or left against medical advice (LAMA) or death. These were considered as outcomes of therapy in this study. Information on demographics (age and sex), clinical characteristics (reason for MICU admission, severity of illness), antibiotic use (indication, total number, generic name, dose, frequency, number of doses per package, number of packaged consumed, and route of administration of antibiotic, utilization of antibiotic), antibiotic cost at the time of the study, antibiotic sensitivity, and length of ICU stay were collected. The severity of illness was assessed using Acute Physiology and Chronic Health Evaluation II (APACHE II) score. Antibiotics were classified using the Anatomical Therapeutic Chemical (ATC) Classification System and their indication was categorized as empirical, prophylaxis and definitive. The utilization of antibiotics in MICU was presented as daily defined dose (DDD) per 100 bed-days, which was calculated using the formula

\[
\text{DDD/100 bed-days} = \frac{\text{Number of units administered in a given period} \times 100}{\text{DDD} \times \text{number of days} \times \text{number of beds} \times \text{occupancy index}}
\]

The number of beds in MICU was 17 and the occupancy index of 0.82 was calculated as follows

\[
\text{Occupancy index} = \frac{\text{Total inpatient service days for a period} \times 100}{\text{Total inpatient bed count} \times \text{number of days in the period}}
\]

The cost per unit of antibiotics was obtained from the hospital pharmacy at the time of study to calculate the direct cost of total antibiotics used for each patient. The percentage of antibiotic sensitivity was calculated as number of sensitive cultures out of total sensitivity tests.

Statistical analysis

The data were entered in Microsoft Excel version 13 and analyzed using IBM-SPSS 20.0 (IBM Corporation, Armonk, NY, USA). Data were expressed as mean value and standard deviation (SD) or median and interquartile range (IQR), and mostly descriptive statistics were used. The Kolmogorov–Smirnov test was used to determine the normality of numeric variables.

Ethics

Ethical approval for this study was obtained from the Institutional Review Committee of Chitwan Medical College.
Table 1. Demographic and clinical characteristics of patient (n = 157).

| Characteristics          | Categories               | n (%)       |
|--------------------------|--------------------------|-------------|
| Age                      | 18–94                    | 50.6 (20.18) |
| Gender                   | Female                   | 91 (58.0)   |
| Reason for admission     | Respiratory illness      | 34 (21.7)   |
|                         | Gastrointestinal illness | 24 (15.3)   |
|                         | Renal illness            | 20 (12.7)   |
|                         | Poisoning                | 18 (11.5)   |
|                         | Reproductive-endocrine illness | 12 (7.6)   |
|                         | Septic shock             | 15 (9.6)    |
|                         | Central nervous system illness | 11 (7.0)  |
|                         | Cardiovascular illness   | 6 (3.8)     |
|                         | Others                   | 17 (10.8)   |
| APACHE II score          | 0–10                     | 41 (26.1)   |
|                         | 11–20                    | 81 (51.6)   |
|                         | 21–30                    | 30 (19.1)   |
|                         | 31–40                    | 5 (3.2)     |
| Length of MICU stay (days)* | 2–16                   | 5 (4)       |
| Outcome of therapy       | Death                    | 25 (15.9)   |
|                         | DOR                      | 20 (12.7)   |
|                         | LAMA                     | 11 (7.0)    |
|                         | Shifted to other wards   | 93 (59.2)   |
|                         | Referral                 | 3 (1.9)     |
|                         | Medical advice           | 5 (3.2)     |

IQR: inter quartile range; APACHE II: Acute Physiology and Chronic Health Evaluation II score; MICU: medical intensive care unit; DOR: discharged on request; LAMA: leaving against medical advice.

A total of 365 antibiotics were prescribed to 157 patients during the period of stay in the MICU (mean ± SD: 2.32 ± 0.989, antibiotic per prescription). The majority of patients (72.0%) were on empirical therapy. The majority (73.15%) of prescribed antibiotics were given parenterally. The total cost of antibiotics prescribed in all patients was US$12,724.34, and the median (IQR) = US$47.67 (US$63.73) per patient, as illustrated in Table 2. Total antibiotic consumption based on DDD per 100 bed-days during the study period was 49.43. Utilization pattern, ATC codes, frequency, and DDD/100 bed-days have been shown in Table 3.

The culture and sensitivity test was carried out in 57.3% of the total patients, of which only 113 specimens were sent for testing. From that, total 20 organisms were isolated, out of which sensitivity test was performed only for *Escherichia coli* (*E. coli*) (n = 10), *Acinetobacter* (n = 2), and *Pseudomonas* sp. (n = 4). The antibiotic sensitivity pattern of three organisms showed that almost all isolates were resistant to meropenem (100%), Colistin, amikacin, ceftriaxone, imipenem, nitrofurantoin, and tigecycline showed the highest susceptibility rate (100%) on *E. coli* followed by piperacillin/tazobactam, polymyxin-B (75%), and ceftriaxone and ceftazidime (50%). Similarly, levofloxacin, colistin, ciprofloxacin, and polymyxin-B had the highest susceptibility rate on *Pseudomonas* spp, whereas colistin had the highest susceptibility for *Acinetobacter*, as depicted in Table 4.

Discussion

This study evaluated the utilization, sensitivity and cost analysis of antibiotics used in the MICU of a tertiary care teaching hospital of Nepal over 2 months. The study revealed that the utilization of antibiotics was considerably high in this setting and a number of such antibiotics were resistant to the isolated strains of microorganism. This study also showed that there was a high variation in the cost of these utilized antibiotics. The median hospital stay was 5 days with median APACHE II score of 17% and 15.9% mortality rate. APACHE II is measured during the first 24 h of ICU admission and objectively quantifies the severity of disease.

The findings of the antibiotic utilization suggested that almost half of the MICU patients received one DDD of an antibiotic every day (DDD/100 bed-days was ~50). This was comparatively lower than a study conducted in a similar setting in Western Nepal (Manipal Teaching Hospital, Pokhara, Nepal) for 4 months, where the utilization was 118.2/100 bed-days. However, this study was conducted in Central Nepal for only 2 months. Furthermore, there is a paucity of evidence from Nepal on antibiotic utilization. A study from Turkey reported a significant reduction in antibiotic utilization from 93.6 to 63.1 DDD/100 patient-days in 1 year (2011–2012), where the absolute change was 30.2 DDD/100 bed-days. The finding of this study showed that 365
Antibiotics were prescribed during the study period, that is, an average of two antibiotics per patient. These data are comparable to that reported in the literature from varying geographic regions and types of patients, which showed it ranged from 1.73 to 5.16–21. We also found that the DDD/100 bed-days for the six most frequently prescribed antibiotics were 8.7 (doxycycline), 7.8 (piperacillin/tazobactam), 6.2 (ceftriaxone), 6.1 (azithromycin), 5.1 (metronidazole), and 4.8 (meropenem). In a study in Western Nepal, in a similar setting, the utilization of penicillin, fluoroquinolones, second-generation cefalosporins, and third-generation cefalosporins were 55.1, 5.34, 0.82, and 13.74 DDD/100 bed-days, respectively.6 In a similar study from India, the five most utilized antimicrobial agents were third-generation cefalosporins (18.48), meropenem (16.47), levofloxacin (15.97), metronidazole (14.65), and ceftriaxone (13.42).22 The acquisition of infection during nosocomial stay, presence of multiple comorbidities, high rate of invasive procedure, and presence of risk factors for infection due to multiple drug resistant pathogens favor high utilization of antibiotics in MICU.3,4 In this study, antibiotics use was empirical in 70% of the patients and definitive in 9.6% of them. Among

| Table 2. Antibiotic use and cost in MICU. |
|------------------------------------------|
| Characteristics                          |
| Indication of antibiotic therapy         |
| Empirical                                |
| Definitive                               |
| Prophylaxis                              |
| Number of antibiotics used               |
| One                                      |
| Two                                      |
| Three                                    |
| Four                                     |
| Five or more                             |
| Route of administration                  |
| Parenteral                               |
| Oral                                     |
| Direct antibiotic cost*                  |
| US$4.14–US$679.00                        |
| US$47.67 (US$63.73)                      |

*Median (IQR) instead of n (%); 1US$ = Nepalese rupees (NRs) 108.54.

There were 128 patients on empirical therapy at the initiation of the treatment and 15 of them switched to the definitive therapy.

| Table 3. Utilization of antibiotics in the MICU (n = 157). |
|----------------------------------------------------------------|
| Name of antibiotic                       | ATC code | Number of prescriptions | Percentage | DDD (g) | DDD/100 bed-days |
|------------------------------------------|----------|-------------------------|------------|---------|------------------|
| Piperacillin/tazobactam                  | J01CR05  | 71                      | 45.2       | 14      | 7.79             |
| Ceftriaxone                              | J01DD04  | 54                      | 34.4       | 2       | 6.14             |
| Metronidazole                            | J01XD01  | 45                      | 28.7       | 1.5     | 5.12             |
| Doxycycline                              | J01AA02  | 38                      | 24.2       | 0.1     | 8.65             |
| Azithromycin                             | J01FA10  | 32                      | 20.4       | 0.3     | 6.07             |
| Meropenem                                | J01DH02  | 28                      | 17.8       | 2       | 4.78             |
| Levofloxacin                             | J01MA12  | 25                      | 15.9       | 0.5     | 2.84             |
| Cefotaxime                               | J01DD01  | 15                      | 9.6        | 4       | 1.28             |
| Amikacin                                 | J01GB06  | 13                      | 8.3        | 1       | 1.11             |
| Amoxicillin/clavulanate                  | J01CR02  | 12                      | 7.6        | 3       | 1.69             |
| Clindamycin                              | J01FF01  | 8                       | 5.1        | 1.8     | 0.91             |
| Imipenem/cilastatin                      | J01DH51  | 6                       | 3.8        | 2       | 0.34             |
| Linezolid                                | J01XX08  | 4                       | 2.5        | 1.2     | 0.45             |
| Ciprofloxacin(P)                         | J01MA02  | 2                       | 1.27       | 0.5     | 0.18             |
| Ciprofloxacin(O)                         | J01MA02  | 2                       | 1.27       | 1       | 0.22             |
| Vancomycin                               | J01XA01  | 3                       | 1.9        | 2       | 0.34             |
| Flucloxacin                              | J01CF05  | 3                       | 1.9        | 2       | 0.34             |
| Ampicillin                               | J01CA01  | 3                       | 1.9        | 2       | 0.51             |
| Cefuroxime                               | J01DC02  | 2                       | 1.3        | 0.5     | 0.45             |
| Colistin                                 | J01XB01  | 2                       | 1.3        | 3MU     | 0.22             |

Total antibiotic consumption: 49.43

ATC: Anatomical Therapeutic Chemical classification; DDD: defined daily dose; P: parenteral; O: oral.
empirically used antibiotics, piperacillin/tazobactam comprised of the major proportion. This may be defined on the basis of disease condition of patients admitted in MICU, where the prevalence of patients with respiratory illness was higher in this study. Likewise, delay in obtaining antibiotic sensitivity reports, and possibility of false-negative results might be other reason to undertake empirical therapy to manage the condition of admitted patients. Antibiotics were used prophylactically in 18.5% of the patients in this study, which is higher than that obtained in other study from South Africa.23

Studies have shown that antibiotics are used as a prophylaxis in several countries. Data from Western European countries suggested that 71% of all patients were receiving antibiotics as prophylaxis or treatment in ICUs.24 A single-centered prospective study in Belgium found 42% were prescribed prophylaxis25 while a nationwide, single-day survey in 52 ICUs of Japan showed 34% of the prescriptions were prophylaxis intravenous (IV) antibiotics.26 In the context of Nepal, the prophylactic use of antibiotic in MICU is not explicitly stated in the literature, but international guidelines on initial antibiotic selection are generally applied in the ICUs of Nepal and empiric choices are made for serious ICU-related infections. However, evidence suggest that patients in ICU are more prone to nosocomial infection, so antibiotics could have been used prophylactically for the prevention of infection from Staphylococcus aureus, Pseudomonas aeruginosa, Clostridioides difficile, and so on.

This study revealed E. coli as the most frequent isolate that demonstrated multidrug resistance to several antibiotics, whereas a study from Indonesia reported P. aeruginosa as the most common pathogen from specimen in ICU.27 We observed a high level of resistance to meropenem (100%), ciprofloxacin (100%), cefotaxime (75%), cotrimoxazole (75%), and levofloxacin (60%) against the most common isolate E. coli. Similar finding was reported by a study conducted in the capital city of Nepal, where E. coli was found highly resistant (>75%) to ampicillin, cefotaxime, cefepime, ciprofloxacin, and levofloxacin.28 Colistin, amikacin, and ceftriaxone demonstrated most sensitivity to most of the isolates in this study. In contrast to this, meropenem was found to be the most sensitive antibiotic against all bacterial isolates from ICU admitted patients in studies conducted in Central and Eastern Nepal.29,30

This study showed that the average cost of antibiotics utilized in the MICU per person was US$47.67, but it varied from US$4 to US$679. The most frequently prescribed antibiotics were the combination of piperacillin and tazobactam (45.2%), and meropenem was the most expensive antibiotics of all (US$4440.70). A study in India reported that patients spent about US$3506.26 on total antibiotic cost or US$32.58 per patient, the combination of piperacillin and tazobactam being the most expensive antibiotics.20 Similarly, the previous study from Western Nepal reported an average expenditure of US$25.1 ± 16.2 on the drugs prescribed in ICU and US$28.83 per patient cost of antimicrobial agents.6 On the contrary, comparisons of antibiotic utilization costs globally could be often deceptive due to the immense alteration of drug prices globally. Overuse of expensive antibiotics such as meropenem and piperacillin/tazobactam in this study depicts extra cost for patients. Different factors may be attributed to the antibiotic use pattern in this study, such as lack of proper drug use policies, lack of appropriate protocols, guidelines, and formulary books. Furthermore, inappropriate monitoring and evaluation of antibiotic use, microbial resistance, lack of continued medical education,

### Table 4. Antibiotic sensitivity in commonly isolated organisms from the MICU.

| Micro-organism isolated (%) sensitivity | E. coli (n = 10) | Acinetobacter (n = 2) | Pseudomonas spp. (n = 4) |
|----------------------------------------|-----------------|----------------------|------------------------|
| Ceftriaxone                            | 50              | 50                   | 66.66                  |
| Piperacillin/tazobactam                | 75              | NT                   | 25                     |
| Meropenem                              | 0               | 0                    | 0                      |
| Imipenem                               | 100             | NT                   | 0                      |
| Cefotaxime                             | 25              | 0                    | 50                     |
| Levofloxacin                           | 40              | NT                   | 100                    |
| Amikacin                               | 100             | 50                   | 66.66                  |
| Colistin                               | 100             | 100                  | 100                    |
| Ciprofloxacin                          | 0               | 0                    | 40                     |
| Cefepime                               | 75              | 50                   | 0                      |
| Nitrofurantoin                         | 100             | NT                   | NT                     |
| Tigecycline                            | 100             | 0                    | 50                     |
| Polymyxin-B                            | 75              | NT                   | 100                    |
| Ceftazidine                            | 50              | 0                    | 50                     |
| Cotrimoxazole                          | 25              | 0                    | NT                     |

NT: not tested.
and lack of clinical pharmacologists or clinical pharmacist are the other associated factors that may cause over- and misuse of antibiotics in hospitals.31

In this study, the majority of the antibiotics were prescribed for parenteral use, which was comparable to previous studies in Western Nepal and India.6,20 MICU provides medical services to severely ill patients who are often unable to take medicines orally. In such condition, parenteral preparations overcome the problems associated with oral administration, providing rapid onset of action, better bioavailability, and speedy symptomatic relief. Besides their advantage, they are associated with more complications, are less patient convenient, and more expensive than oral preparations leading to increase in overall healthcare cost to patients.32 Conversion of IV antibiotics to oral could benefit the patients by increasing the possibility of earlier discharge from hospital, eliminating adverse events associated with IV therapy, reducing the risk of acquiring a hospital infection, increasing patient comfort and mobility, and lowering the cost of daily antibacterial use.33,34

There are a number of limitations to this study. We explored the antibiotic utilization pattern over a period of 2 months; hence, the influence of seasonal variations on disease pattern and antibiotics utilization could not be considered. Not all the antibiotics were tested for sensitivity; therefore, the sensitivity prevalence may be higher than those reported in this study. There were also cases which were not discharged, rather LAMA or DOR or shifted to other wards, and a clear outcome in these patients could not be known. Similarly, a power analysis and sample size calculation was also not performed in the study. Likewise, the total healthcare cost of the individual patient was outside the scope of this study, and therefore, we were only able to calculate the cost for antibiotics use. Moreover, the overdose of antibiotics could give rise to the risk of developing Clostridium difficile infection, but whether this was true remains beyond the scope of this study. But this could be considered as a potential area to explore as a future study. Finally, the clinical microbiology part of the study could have been strengthened. Despite these limitations, this study provides an insight into the antibiotic use in ICU and the cost associated with it. The findings might be beneficial for policy formulation of antibiotics in Nepal.

Conclusion

This study suggests that the utilization of antibiotics and their cost in MICU of Central Nepal is high. E. coli was the most common isolate that demonstrated resistance toward multiple antibiotics that could pose a challenging issue in the therapeutic outcome of patients in the MICU. These findings highlight an urgent need for standard guidelines, protocols, educational intervention, surveillance, and antibiotic stewardship program in this setting. It also urges for the rational use of antibiotics and their subsequent pharmacoeconomic evaluation.

Acknowledgements

The authors thank the Chitwan Medical College Teaching Hospital for providing support to conduct this study.

Author contributions

N.R.M. contributed to the conceptualization. N.R.M. contributed to the data curation. N.R.M., S.S. (Shakti Shrestha), and S.S. (Sabina Sankhi) contributed to the formal analysis. The funding acquisition is nil. N.R.M. contributed to the methodology. N.R.M. contributed to the project administration. N.R.M., S.S. (Shakti Shrestha), S.S. (Sabina Sankhi), and A.G. contributed to the visualization. N.R.M. and S.S. (Sabina Sankhi) contributed to the writing—original draft. N.R.M., S.S. (Shakti Shrestha), S.S. (Sabina Sankhi), N.P., and A.P. contributed to the writing—review and editing. A.G. contributed to the supervision.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval for this study was obtained from the Institutional Review Committee of Chitwan Medical College Teaching Hospital (CMC/IRC/47).

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

The patients or the caretakers were informed about the details of the study, and their written consent was obtained prior to data collection.

ORCID iD

Nirmal Raj Marasine https://orcid.org/0000-0003-4353-382X

Data availability

The raw data used to support the findings of this study are made available from the corresponding author upon reasonable request.

References

1. Krivoy N, El-Ahal WA, Bar-Lavie Y, et al. Antibiotic prescription and cost patterns in a general intensive care unit. Pharm Pract (Granada) 2007; 5(2): 67–73.
2. Siwakoti S, Subedi A, Sharma A, et al. Incidence and outcomes of multidrug-resistant gram-negative bacteria infections in intensive care unit from Nepal—a prospective cohort study. Antimicrob Resist Infect Control 2018; 7(1): 114.
3. Walther SM, Erlandsson M, Burman LG, et al. Antibiotic prescription practices, consumption and bacterial resistance in a...
cross section of Swedish intensive care units. *Acta Anaesthesiol Scand* 2002; 46(9): 1075–1081.
4. Weber RJ, Kane SL, Oriolo VA, et al. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. *Crit Care Med* 2003; 31(1 Suppl.): S17–S24.
5. Roder BL, Niels J, Magnusson P, et al. Antibiotic usage in an intensive care unit in a Danish university hospital. *J Antimicrob Chemother* 1993; 32(4): 633–642.
6. Shankar PR, Partha P, Dubey AK, et al. Intensive care unit drug utilization in a teaching hospital in Nepal. *Kathmandu Univ Med J (KUMJ)* 2005; 3(2): 130–137.
7. Alharthi NR, Kenawy G and Eldalo AS. Antibiotics’ prescribing pattern in intensive care unit in Taif, Saudi Arabia. *Saudi J Health Sci* 2019; 8(1): 47.
8. Wunderink RG, Srinivasan A, Barie PS, et al. Antibiotic Stewardship in the Intensive Care Unit. An official American Thoracic Society Workshop report in collaboration with the AACN, CHEST, CDC, and SCCM. *Ann Am Thorac Soc* 2020; 17(5): 531–540.
9. World Health Organization. Antibiotic resistance, https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance (accessed 26 December 2020).
10. Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. *Crit Care* 2001; 5(4): 189–195.
11. Oxford J and Kozlov R. Antibiotic resistance—a call to arms for primary healthcare providers. *Int J Clin Pract Suppl* 2013;180(): 1–3.
12. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—time to react is now. *Drug Resist Updat* 2011; 14(2): 118–124.
13. Davies PD. Does increased use of antibiotics result in increased antibiotic resistance? *Clin Infect Diseases* 2004; 39(1): 18–19.
14. Patrick DM, Marra F, Hutchinson J, et al. Per capita antibiotic consumption: how does a North American jurisdiction compare with Europe? *Clin Infect Diseases* 2004; 39(1): 11–17.
15. Maxwell SRJ and Wilkinson K. Writing safe and effective prescriptions in a hospital Karden. *J R Coll Physicians Edinb* 2007; 37: 348–351.
16. World Health Organization. WHO collaborating centre for drug statistics methodology: guidelines for ATC classification and DDD assignment. Oslo: World Health Organization, 2020.
17. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. *Crit Care Med* 1985; 13(10): 818–829.
18. Bozkurt F, Kayar S, Tekin R, et al. Analysis of antimicrobial consumption and cost in a teaching hospital. *J Infect Public Health* 2014; 7(2): 161–169.
19. Hanssens Y, Ismaeil BB, Kamha AA, et al. Antibiotic prescribing pattern in a medical intensive care unit in Qatar. *Saudi Med J* 2005; 26(8): 1269–1276.
20. Anand N, Nagendra Nayak IM, Advaitha MV, et al. Antimicrobial agents’ utilization and cost pattern in an Intensive Care Unit of a Teaching Hospital in South India. *Indian J Crit Care Med* 2016; 20(5): 274–279.
21. Amin VH, Hamdolah S, Behzad B, et al. Antibiotic-use patterns in an intensive care unit of a hospital in Iran: how challenging with patient safety? *Adv Biosci* 2014; 5(1): 25–28, http://www.hindex.org/2014/article.php?page=389 (accessed 26 December 2020).
22. Williams A, Mathai AS and Phillips AS. Antibiotic prescription patterns at admission into a tertiary level intensive care unit in Northern India. *J Pharm Bioallied Sci* 2011; 3(4): 531–536.
23. Dlamini NN, Meyer JC, Kruger D, et al. Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: a pilot study and implications. *Hosp Pract (1999)* 2019; 47(2): 88–95.
24. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009; 302(21): 2323–2329, https://jamanetwork.com/journals/jama/article-abstract/184963 (accessed 16 June 2021).
25. De Bus L, Gadeyne B, Steen J, et al. A complete and multifaceted overview of antibiotic use and infection diagnosis in the intensive care unit: results from a prospective four-year registration. *Critical Care* 2018; 22(1): 241.
26. Ohnuma T, Hayashi Y, Yamashita K, et al. A nationwide survey of intravenous antimicrobial use in intensive care units in Japan. *Int J Antimicrob Agents* 2018; 51(4): 636–641.
27. Radij M, Fauziah S and Arabinuko N. Antibiotic susceptibility pattern of bacterial pathogens in the intensive care unit of Fatmawati Hospital, Indonesia. *Asian Pac J Trop Biomed* 2011; 1(1): 39–42.
28. Parajuli NP, Acharya SP, Mishra SK, et al. High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal. *Antimicrob Resist Infect Control* 2017; 6: 67.
29. Sanjana RK and Majhi PC. Microbial infection and antibiotic patterns among intensive care unit patients in a tertiary hospital in Central Nepal. *J College Med Sci Nepal* 2012; 8(3): 1–8.
30. Sarraf D, Phunyalb M, Mandals M, et al. Utilization pattern of antimicrobial agents and its culture sensitivity pattern in intensive care units in a tertiary care center in eastern Nepal. *Nepal Med College J* 2015; 17(3–4): 107–112.
31. Horn E and Jacobi J. The critical care clinical pharmacist: evolution of an essential team member. *Crit Care Med* 2006; 34(3 Suppl.): S46–S51.
32. Shrayteh ZM, Rahal MK and Malaeb DN. Practice of switch from intravenous to oral antibiotics. *SpringerPlus* 2014; 3(1): 717.
33. Hogan-Murphy D, Waqas S, Tuite H, et al. What stops doctors switching from intravenous to oral antibiotics? *Irish Med J* 2019; 112(8): 987.
34. Downen J and Jaeger C. Quality improvement of intravenous to oral medication conversion using Lean Six Sigma methodologies. *BMJ Open Qual* 2020; 9(1): e000804.